$385.73
-4.47[-1.15%]
At close: Apr 24
$385.73
0[0.00%]
After Hours: 4:00PM EDT
West Pharmaceutical Servs
(NYSE:WST)West Pharmaceutical Servs Stock (NYSE:WST), Analyst Ratings, Price Targets, Predictions
West Pharmaceutical Services Inc has a consensus price target of $404.33, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from UBS, Keybanc, and Jefferies on February 16, 2024, February 13, 2024, and February 7, 2024. With an average price target of $460.33 between UBS, Keybanc, and Jefferies, there's an implied 19.34% upside for West Pharmaceutical Services Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
UBS
Keybanc
Jefferies
Stephens & Co.
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for West Pharmaceutical Servs
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/16/2024 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -2.78% | UBS | John Sourbeer | $400 → $375 | Maintains | Neutral | Get Alert |
| 02/13/2024 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 21.85% | Keybanc | Paul Knight | $440 → $470 | Maintains | Overweight | Get Alert |
| 02/07/2024 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 38.96% | Jefferies | David Windley | $323 → $536 | Upgrade | Hold → Buy | Get Alert |
| 10/27/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 1.11% | Stephens & Co. | Jacob Johnson | $420 → $390 | Maintains | Overweight | Get Alert |
| 08/30/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 14.07% | Keybanc | Paul Knight | $415 → $440 | Maintains | Overweight | Get Alert |
| 08/21/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 7.59% | Keybanc | Paul Knight | $385 → $415 | Maintains | Overweight | Get Alert |
| 07/28/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -0.19% | Keybanc | Paul Knight | $375 → $385 | Maintains | Overweight | Get Alert |
| 07/17/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 8.88% | Stephens & Co. | Jacob Johnson | $400 → $420 | Maintains | Overweight | Get Alert |
| 06/16/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 5% | B of A Securities | Derik De Bruin | $390 → $405 | Upgrade | Neutral → Buy | Get Alert |
| 04/11/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 3.7% | Stephens & Co. | Jacob Johnson | $330 → $400 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/17/2023 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -2.78% | Keybanc | Paul Knight | $315 → $375 | Maintains | Overweight | Get Alert |
| 12/14/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -35.19% | Deutsche Bank | Justin Bowers | → $250 | Initiates | → Hold | Get Alert |
| 12/02/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -18.34% | Keybanc | Paul Knight | $350 → $315 | Maintains | Overweight | Get Alert |
| 11/30/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -35.19% | UBS | John Sourbeer | → $250 | Initiates | → Neutral | Get Alert |
| 10/28/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -35.19% | B of A Securities | Derik De Bruin | $385 → $250 | Downgrade | Buy → Neutral | Get Alert |
| 10/28/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -9.26% | Keybanc | Paul Knight | $400 → $350 | Maintains | Overweight | Get Alert |
| 07/29/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | -10.56% | Stephens & Co. | Jacob Johnson | $330 → $345 | Maintains | Equal-Weight | Get Alert |
| 04/29/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 6.29% | B of A Securities | Derik De Bruin | $475 → $410 | Maintains | Buy | Get Alert |
| 04/29/2022 | WST | Buy Now | West Pharmaceutical Servs | $385.73 | 3.7% | Keybanc | Paul Knight | $475 → $400 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for West Pharmaceutical Servs (WST)?
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by UBS on February 16, 2024. The analyst firm set a price target for $375.00 expecting WST to fall to within 12 months (a possible -2.78% downside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by UBS, and West Pharmaceutical Servs maintained their neutral rating.
When was the last upgrade for West Pharmaceutical Servs (WST)?
The last upgrade for West Pharmaceutical Services Inc happened on February 7, 2024 when Jefferies raised their price target to $536. Jefferies previously had a hold for West Pharmaceutical Services Inc.
When was the last downgrade for West Pharmaceutical Servs (WST)?
The last downgrade for West Pharmaceutical Services Inc happened on October 28, 2022 when B of A Securities changed their price target from $385 to $250 for West Pharmaceutical Services Inc.
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $400.00 to $375.00. The current price West Pharmaceutical Servs (WST) is trading at is $385.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.